Toralizumab

From Self-sufficiency
Jump to: navigation, search
Toralizumab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target CD40 ligand
Identifiers
CAS Number 252662-47-8
ATC code none
Chemical data
Molar mass 148,426 Daltons
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Toralizumab (IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).[1]

In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5C8), the trials were halted.[2]

The drug was developed by IDEC Pharmaceuticals Corporation.

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Toralizumab, American Medical Association.
  2. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.